SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

EL BEITUNE, Patrícia et al. Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children. Braz J Infect Dis [online]. 2004, vol.8, n.2, pp. 140-150. ISSN 1413-8670.  http://dx.doi.org/10.1590/S1413-86702004000200004.

    1. Brocklehurst P., Wolmink J. Antiretroviral for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002 (2):CD003510. [ Links ]

    2. Mofenson L.M., Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002;30(2):200-15. [ Links ]

    3. Kourtis A.P. Prevention of perinatal HIV transmission: current status and future developments in antiretroviral therapy. Drugs 2002;62(15):2213-20. [ Links ]

    4. Taylor G.P., Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf 2001;24(9): 683-702. [ Links ]

    5. Jungmann E.M., Mercey D., DeRuiter A., et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001;77(6):441-3. [ Links ]

    6. Centers for Disease Control and Prevention, U.S. Public Health Service Task Force. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatan HIV-1 transmission in the United States. MMWR Recomm Rep 2002;51(RR-18):1-38. [ Links ]

    7. CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):39-82. [ Links ]

    8. Sperling R.S., Shapiro D.E., McSherry G.D., et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trials Group 076 Study. AIDS 1998;12(14):1805-13. [ Links ]

    9. Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999;353(9155):773-80. [ Links ]

    10. Fiscus S.A., Adimora A.A., Funk M.L., et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 2002;21:664-8. [ Links ]

    11. Wade N.A., Birkhead G.S., Warren B.L., et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339(20):1409-14. [ Links ]

    12. Shaffer N., Bulterys M., Simonds R.J.. Short courses of zidovudine and perinatal transmission of HIV. N Eng J Med 1999;340(13):1042-3. [ Links ]

    13. Stiehm E.R., Lambert J.S., Mofenson L.M. et al. Efficacy of zidovudine and hyperimmune human immunodeficiency virus immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999;179(3):567-75. [ Links ]

    14. Van Rompay K.K., Otsyula M.G., Marthas M.L., et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995;39(1):125-31. [ Links ]

    15. Tsay C.C., Follis K.E., Sabo A., et al. Prevention of SIV infection in macaques by (R)-9(2-phosphonylmethoxypropyl) adanine. Science 1995;270(5239):1197-9. [ Links ]

    16. Bottiger D., Johansson N.G., Samuelsson B., et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre-and postexposure administration of BEA-005. AIDS 1997;11(2):157-62. [ Links ]

    17. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353(9158):1035-9. [ Links ]

    18. Sandberg J.A., Binienda Z., Lipe G., et al. Placental transfer and fetal disposition of 2'3'-dideoxycytidine and 2',3'-dideoxynosine in the rhesus monkey. Drug Metab Dispos 1995;23(8):881-4. [ Links ]

    19. Qian M., Bui T., Ho R.J.Y., Unadkat J.D. Metabolism of 3'-azido-3'deoxythymidine (AZT) in human placental trophoblasts and hofbauer cells. Biochem Pharmacol 1994;48(2):383-9. [ Links ]

    20. Dancis J., Lee J.D., Mendoza S., Liebes L.. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6(1):2-6. [ Links ]

    21. Sandberg J.Á., Binienda Z., Lipe G., Slikker Jr W. Placental transfer and fetal disposition of ddC and ddI. Toxicologist 1994;14:434. [ Links ]

    22. Phuapradit W., Sirinavin S., Taneepanichskul S. et al. Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection. Aust N Z J Obstet Gynaecol 1998;38(3):288-92. [ Links ]

    23. Bhadrakom C., Simonds R.J., Mei J.V., et al. Oral zidovudine during labor to prevent perinatal HIV transmission, Bagkok: tolerance and zidovudine concentration in cord blood. AIDS 2000;14(5):509-16. [ Links ]

    24. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2002. Wilmington, NC: Registry Coordinating Center 2002. [ Links ]

    25. Lipshultz S.E., Easley K.A., Orav E.J. et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000;343(11):759-66. [ Links ]

    26. Carneiro M., Sanchéz A., Maneiro W. et al. Vertical HIV-1 Transmission: prophylaxis and paediatric follow-up. Placenta 2001;22(A):S13-S8. [ Links ]

    27. Culnane M., Fowler M.G., Lee S.S., et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999;281(2):151-7. [ Links ]

    28. Zuccotti G..V., Agostoni C., D'Auria E., et al. Infant growth after in utero exposure to zidovudine. JAMA 1999;282(6):527-9. [ Links ]

    29. Loubery-Unique C., Gautier A., Vauzelle-Gardier C., et al. Antiretroviral agents and pregnancy: mitochondrial dysfunction and nucleoside analogs. Therapie 2001;56(3):261-6. [ Links ]

    30. Brinkman K., Ter-Hofstede H.J.M., Burger D.M., et al. Adverse effects of reverse transcriptase inhibitors: mitochondria toxicity as common pathway. AIDS 1998;12:1735-44. [ Links ]

    31. Martin J.L., Brown D.E., Matthews-Dais N., Reardon J.E. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38(12):2743-9. [ Links ]

    32. Strauss A.W., Bennett M.J., Rinaldo P., et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol 1999;23(2):100-12. [ Links ]

    33. Ibdah J.Á., Yang Z., Bennett M.J. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 2000;71(1-2):182-9. [ Links ]

    34. Blanche S., Tardieu M., Rustin P., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354(9184):1084-9. [ Links ]

    35. Lindegren M.L, Rhodes P., Gordon L et al. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000;918:222-35. [ Links ]

    36. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol 2000;25(3):261-8. [ Links ]

    37. De-Souza R.S., Gomez-Marin O., Scott G.B., et al. Effect of prenatal zidovudine on disease progression in perinatally HIV-1-infected infants. J Acquir Immune Defic Syndr 2000;24(2):154-61. [ Links ]

    38. Shah M.M., Li Y. & Christensen R.D. Effects of perinatal zidovudine on hematopoiesis: a comparison of effects on progenitors from human fetuses versus mothers. AIDS 1996;10:1239-41. [ Links ]

    39. Watson W.J., Stevens T.P. & Weinberg G.A.. Profound anemia in a newborn infant of a mother receiving antiretroviral therapy. Ped Infect Dis J 1997;17:435-6. [ Links ]

    40. Taha T.E., Kumwenda N., Gibbons A., et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 2002;16(6):851-8. [ Links ]

    41. Hanson I.C., Antonelli T.A., Sperling R.S., et al. Lack of tumors in infants with perinatal HIV-exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(5):463-7. [ Links ]

    42. Olivero A.O., Anderson L.M., Diwan B.A., et al. Transplacental effects of 3'-azido-2',3' dideoxythymidine: tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89(21):1602-8. [ Links ]

    43. Mandelbrot L., Landreau-Mascaro A., Rekacewicz C., et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285(16):2083-93. [ Links ]

    44. Silverman N.S., Watts D.H., Hitti J., et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998;6(6):237-43. [ Links ]

    45. Lange J., Stellato R., Brinkman K., et al. Review of neurological adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA study. In: Program and abstracts: 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada (Abstract 250), 1999. [ Links ]

    46. Landreau-Mascaro A ., Barret B., Mayaux M.J., et al. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002;359(9306):583-4. [ Links ]

    47. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol 2002;29(5):484-94. [ Links ]

    48. Flexner C., Hendrix C.W. Pharmacology of antiretroviral agents. In: DeVita VT, Hellman S, Rosenberg AS, eds. AIDS: etiology, diagnosis, treatment and prevention. 4th ed. Philadelphia: Lippincott-Raven 1997:479-93. [ Links ]

    49. Flexner C. HIV-Protease Inhibitors. N Engl J Med 1998;338(18):1281-92. [ Links ]

    50. Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22. [ Links ]

    51. Ho D.D., Neumann A .U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6. [ Links ]

    52. Lorenzi P., Spicher V.M., Laubereau B., et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study. AIDS 1998;12(18):F241-7. [ Links ]

    53. The European Collaborative Study and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14(18):2913-20. [ Links ]

    54. Martin R., Boyer P., Hammill H., et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. J Pediatr 1997;131(6):851-6. [ Links ]

    55. Leroy V., Ladner J., Nyiraziraje M., et al. Effect ofHIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS 1998;12(6);643-50. [ Links ]

    56. Brocklehurst P., French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998;105(8):836-48. [ Links ]

    57. Tuomala R.E., Shapiro D., Mofenson L.M., et al. Antiretroviral therapy during pregnancy and the risk of adverse outcome. N Engl J Med 2002;346:1863-70. [ Links ]